Summary

GBI Research, the leading business intelligence provider, has released its latest research “Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value”, which provides insights into metabolic disease therapeutics marled until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major metabolic diseases including Diabetes, Obesity and Dyslipidemia. The report also provides the share of generics in global metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each three indications. The report examines the global metabolic diseases treatment usage patterns. In addition, the geographical distribution of metabolic diseases and market across the US, the top five countries of Europe and in Japan are provided in the report. The report also includes insights into the metabolic diseases R&D product pipeline and explores the competitive landscape including major players in metabolic disorder therapeutics market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in metabolic disorder therapeutics market.

Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global metabolic disorder therapeutics market for the three indications that includes Diabetes, Obesity and Dyslipidemia.
- Data and analysis on the metabolic disorder therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the metabolic disorder therapeutics market from 2002 to 2010, with forecasts to 2017 for three indications which includes diabetes, obesity and dyslipidemia
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in global metabolic disorder therapeutics market and for the market of each indication that is covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global metabolic disorder market including top companies benchmarking. The key companies studied in this report are Pfizer Inc., Novo Nordisk, Sanofi, Takeda, Eli Lilly, GlaxoSmithKline and Merck & Co. Inc.
- Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the metabolic disorder therapeutics market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
 

1.1 List of Tables 7
1.2 List of Figures 9
2 Metabolic Disorders Therapeutics Market to 2017 - Introduction 12
2.1 Overview 12
2.2 GBI Research Report Guidance 13
3 Metabolic Disorders Therapeutics Market to 2017 - Market Characterization 14
3.1 Introduction 14
3.2 Revenue Forecast for the Metabolic Disorders Therapeutics Market to 2017 15
3.2.1 Revenues 15
3.2.2 Revenue by Country 16
3.2.3 Generic Share 18
3.2.4 Annual Cost of Treatment (ACT) 19
3.3 Treatment Usage Patterns 20
3.3.1 Diseased Population 22
3.3.2 Treatment Seeking Population 23
3.3.3 Diagnosed Population 24
3.3.4 Prescription Population 25
3.4 Drivers and Restraints of the Global Metabolic Disorders Therapeutics Market 26
3.4.1 Drivers for the Metabolic Disorders Therapeutics Market 26
3.4.2 Restraints for the Metabolic Disorders Therapeutics Market 27
4 Metabolic Disorders Therapeutics Market to 2017 - Geographical Landscape 28
4.1 Revenue Analysis by Geography 28
4.2 The US 30
4.2.1 Revenue 30
4.2.2 Annual Cost of Treatment 31
4.2.3 Treatment Usage Pattern 32
4.3 Top Five Countries of Europe 37
4.3.1 Revenue 37
4.3.2 Annual Cost of Treatment 39
4.3.3 Treatment Usage Pattern 40
4.4 Japan 45
4.4.1 Revenue 45
4.4.2 Annual Cost of Treatment 46
4.4.3 Treatment Usage Pattern 47
5 Metabolic Disorders Therapeutics Market to 2017 - Diabetes Market 52
5.1 Introduction 52
5.2 Market Forecasts 52
5.2.1 Revenue by Country 54
5.2.2 Generic Share 55
5.3 Annual Cost of Treatment 56
5.4 Treatment Flow Algorithm 57
5.5 Treatment Usage Patterns 58
5.5.1 Diseased Population 59
5.5.2 Treatment Seeking Population 60
5.5.3 Diagnosed Population 61
5.5.4 Prescription Population 62
5.6 Major Marketed Products 63
5.7 Drivers and Restraints of the Diabetes Market 64
5.7.1 Drivers of the Diabetes Market 64
5.7.2 Restraints of the Diabetes Market 65
6 Metabolic Disorders Therapeutics Market to 2017 - Obesity Market 66
6.1 Introduction 66
6.2 Market Forecasts 66
6.2.1 Revenue by Country 67
6.2.2 Generic Share 68
6.3 Annual Cost of Treatment 69
6.4 Treatment Flow Algorithm 70
6.5 Treatment Usage Patterns 71
6.5.1 Diseased Population 73
6.5.2 Treatment Seeking Population 74
6.5.3 Diagnosed Population 75
6.5.4 Prescription Population 76
6.6 Major Marketed Products 77
6.7 Drivers and Restraints of the Obesity Market 77
6.7.1 Drivers of the Obesity Market 77
6.7.2 Restraints of the Obesity Market 78
7 Metabolic Disorders Therapeutics Market to 2017 - Dyslipidemia Market 79
7.1 Introduction 79
7.2 Market Forecasts 79
7.2.1 Revenue by Country 80
7.2.2 Generic Share 81
7.3 Annual Cost of Treatment 82
7.4 Treatment Flow Algorithm 83
7.5 Treatment Usage Patterns 84
7.5.1 Diseased Population 85
7.5.2 Treatment Seeking Population 86
7.5.3 Diagnosed Population 87
7.5.4 Prescription Population 88
7.6 Major Marketed Products 89
7.7 Drivers and Restraints of the Dyslipidemia Market 89
7.7.1 Drivers of the Dyslipidemia Market 89
7.7.2 Restraints of the Dyslipidemia Market 89
8 Metabolic Disorders Therapeutics Market to 2017 - Pipeline Analysis 90
8.1 Introduction 90
8.2 Diabetes: Research and Development Pipeline 92
8.2.1 Overview 92
8.2.2 Pipeline by Clinical Phases of Development 92
8.3 Obesity: Research and Development Pipeline 108
8.3.1 Overview 108
8.3.2 Pipeline by Clinical Phases of Development 108
8.4 Dyslipidemia: Research and Development Pipeline 113
8.4.1 Overview 113
8.4.2 Pipeline by Clinical Phases of Development 114
8.5 Profiles of Promising Drugs in the Diabetes Market 118
8.5.1 rhGAD65 (Diamyd) 118
8.5.2 DiaPep277 119
8.5.3 Otelixizumab 119
8.5.4 BMS-512148 (dapagliflozin) 120
8.5.5 D-Tagatose 121
8.5.6 JNJ-28431754 (canagliflozin) 121
8.5.7 Teplizumab 122
8.5.8 Lixisenatide 123
8.6 Profiles of Promising Drugs in the Obesity Market 124
8.6.1 Contrave (Buropion SR + Naltrexone) 124
8.6.2 Victoza (liraglutide) 124
8.6.3 Cametor (cetilistat) 126
8.7 Profiles of Promising Drugs in the Dyslipidemia Market 127
8.7.1 RG1658 (Dalcetrapib, JTT-705, RO4607381) 127
8.7.2 MK-0524A (Cordaptive, niacin + laropiprant) 128
8.7.3 AMR101 (LAX-101, Miraxion) 129
8.7.4 MK-0859 (anacetripib) 130
9 Metabolic Disorders Therapeutics Market to 2017 - Competitive Landscape 131
9.1 Company Profiles for Metabolic Disorders 131
9.1.1 Pfizer Inc. 131
9.1.2 Novo Nordisk 133
9.1.3 Sanofi 134
9.1.4 Takeda 136
9.1.5 Eli Lilly 137
9.1.6 GlaxoSmithKline (GSK) 138
9.1.7 Merck & Co Inc 139
9.1.8 Amylin Pharmaceuticals 141
10 Metabolic Disorders Therapeutics Market to 2017 - Strategic Consolidations 142
10.1 Mergers and Acquisitions 142
10.1.1 Segmentation by Indication 142
10.1.2 Segmentation by Deal Value 145
10.1.3 Segmentation by Geography 147
10.2 Co-Development Deals 148
10.2.1 Summary of Co-Development Deals 151
10.3 Licensing Deals 154
10.3.1 Summary of Licensing Deals 159
11 Metabolic Disorders Therapeutics Market to 2017 - Appendix 162
11.1 Market Definitions 162
11.2 Abbreviations 162
11.3 Research Methodology 164
11.3.1 Coverage 164
11.3.2 Secondary Research 164
11.3.3 Primary Research 165
11.3.4 Therapeutic Landscape 165
11.3.5 Geographical Landscape 168
11.3.6 Pipeline Analysis 168
11.3.7 Competitive Landscape 168
11.4 Expert Panel Validation 168
11.5 Contact Us 168
11.6 Disclaimer 169
11.7 Sources 169

1.1 List of Tables
Table 1: Metabolic Disorders Therapeutics Market, Global, Obesity Classification by Body Mass Index (BMI), 2010 14
Table 2: Metabolic Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010 15
Table 3: Metabolic Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 16
Table 4: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 17
Table 5: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 17
Table 6: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 19
Table 7: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 19
Table 8: Metabolic Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 21
Table 9: Metabolic Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 21
Table 10: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 28
Table 11: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 29
Table 12: Metabolic Disorders Therapeutics Market, The US, Revenue ($bn), 2002-2010 30
Table 13: Metabolic Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017 30
Table 14: Metabolic Disorders Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2010 31
Table 15: Metabolic Disorders Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017 31
Table 16: Metabolic Disorders Therapeutics Market, The US, Treatment Usage Pattern (million), 2002-2010 32
Table 17: Metabolic Disorders Therapeutics Market, The US, Treatment Usage Pattern (million), 2010-2017 33
Table 18: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010 37
Table 19: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2017 38
Table 20: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2010 39
Table 21: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 39
Table 22: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2002-2010 40
Table 23: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2010-2017 41
Table 24: Metabolic Disorders Therapeutics Market, Japan, Revenue ($bn), 2002-2010 45
Table 25: Metabolic Disorders Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017 45
Table 26: Metabolic Disorders Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010 46
Table 27: Metabolic Disorders Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017 46
Table 28: Metabolic Disorders Therapeutics Market, Japan, Treatment Usage Pattern (million), 2002-2010 47
Table 29: Metabolic Disorders Therapeutics Market, Japan, Treatment Usage Pattern (million), 2010-2017 48
Table 30: Diabetes Therapeutics Market, Global, Revenue ($bn), 2002-2010 53
Table 31: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 53
Table 32: Diabetes Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 54
Table 33: Diabetes Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 55
Table 34: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 56
Table 35: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 56
Table 36: Diabetes Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010 58
Table 37: Diabetes Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017 59
Table 38: Diabetes Therapeutics Market, Global, Major Drugs, 2009-2010 64
Table 39: Obesity Therapeutics Market, Global, Revenue ($bn), 2002-2010 66
Table 40: Obesity Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 67
Table 41: Obesity Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 67
Table 42: Obesity Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 68
Table 43: Obesity Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 69
Table 44: Obesity Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 69
Table 45: Obesity Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010 72
Table 46: Obesity Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017 72
Table 47: Obesity Therapeutics Market, Global, Major Drugs, 2002-2017 77
Table 48: Dyslipidemia Therapeutics Market, Global, Revenue ($bn), 2002-2010 79
Table 49: Dyslipidemia Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 80
Table 50: Dyslipidemia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 80
Table 51: Dyslipidemia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 81
Table 52: Dyslipidemia Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 82
Table 53: Dyslipidemia Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 82
Table 54: Dyslipidemia Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010 84
Table 55: Dyslipidemia Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017 85
Table 56: Dyslipidemia Therapeutics Market, Global, Major Drugs, 2002-2017 89
Table 57: Diabetes Therapeutics Market, Global, Pre-Clinical/Discovery Phase, 2010 93
Table 58: Diabetes Therapeutics Market, Global, Phase I, 2010 97
Table 59: Diabetes Therapeutics Market, Global, Phase II, 2010 101
Table 60: Diabetes Therapeutics Market, Global, Phase III, 2010 105
Table 61: Diabetes Therapeutics Market, Global, NDA/Filed Molecules, 2010 107
Table 62: Obesity Therapeutics Market, Global, Pre-Clinical/Discovery Phase, 2010 109
Table 63: Obesity Therapeutics Market, Global, Phase I, 2010 111
Table 64: Obesity Therapeutics Market, Global, Phase II, 2010 112
Table 65: Obesity Therapeutics Market, Global, Phase III, 2010 112
Table 66: Obesity Therapeutics Market, Global, NDA/Filed Molecules, 2010 112
Table 67: Dyslipidemia Therapeutics Market, Global, Pre-Clinical/Discovery Phase, 2010 114
Table 68: Dyslipidemia Therapeutics Market, Global, Phase I, 2010 115
Table 69: Dyslipidemia Therapeutics Market, Global, Phase II, 2010 116
Table 70: Dyslipidemia Therapeutics Market, Global, Phase III, 2010 117
Table 71: Metabolic Disorders Therapeutics Market, M&A Deals, 2009-2011 143
Table 72: Metabolic Disorders Therapeutics Market, M&A Top Deals by Value ($m), 2009-2011 146
Table 73: Metabolic Disorders Therapeutics Market, Co-Development, By Geography, 2009-2011 149
Table 74: Metabolic Disorders Therapeutics Market, Licensing Deals, By Geography, 2009-2011 155

 1.2 List of Figures
Figure 1: Metabolic Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 14
Figure 2: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 15
Figure 3: Metabolic Disorders Therapeutics Market, Global, Generic Share, 2010 and 2017 17
Figure 4: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 18
Figure 5: Metabolic Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 19
Figure 6: Metabolic Disorders Therapeutics Market, Global, Diseased Population (million), 2002-2017 21
Figure 7: Metabolic Disorders Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 22
Figure 8: Metabolic Disorders Therapeutics Market, Global, Diagnosis Population (million), 2002-2017 23
Figure 9: Metabolic Disorders Therapeutics Market, Global, Prescription Population (million), 2002-2017 24
Figure 10: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 27
Figure 11: Metabolic Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2017 29
Figure 12: Metabolic Disorders Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2017 30
Figure 13: Metabolic Disorders Therapeutics Market, The US, Treatment Usage Pattern (million), 2002-2017 31
Figure 14: Metabolic Disorders Therapeutics Market, The US, Diseased Population (million), 2002-2017 32
Figure 15: Metabolic Disorders Therapeutics Market, The US, Treatment Seeking Population (million), 2002-2017 33
Figure 16: Metabolic Disorders Therapeutics Market, The US, Diagnosed Population (million), 2002-2017 34
Figure 17: Metabolic Disorders Therapeutics Market, The US, Prescription Population (million), 2002-2017 35
Figure 18: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2017 36
Figure 19: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017 38
Figure 20: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2002-2017 39
Figure 21: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Diseased Population (million), 2002-2017 40
Figure 22: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population (million), 2002-2017 41
Figure 23: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (million), 2002-2017 42
Figure 24: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Prescription Population (million), 2002-2017 43
Figure 25: Metabolic Disorders Therapeutics Market, Japan, Revenue Forecasts ($bn), 2002-2017 44
Figure 26: Metabolic Disorders Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2017 45
Figure 27: Metabolic Disorders Therapeutics Market, Japan, Treatment Usage Pattern (million), 2002-2017 46
Figure 28: Metabolic Disorders Therapeutics Market, Japan, Diseased Population (million), 2002-2017 47
Figure 29: Metabolic Disorders Therapeutics Market, Japan, Treatment Seeking Population (million), 2002-2017 48
Figure 30: Metabolic Disorders Therapeutics Market, Japan, Diagnosed Population (million), 2002-2017 49
Figure 31: Metabolic Disorders Therapeutics Market, Japan, Prescription Population (million), 2002-2017 50
Figure 32: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 52
Figure 33: Diabetes Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 53
Figure 34: Diabetes Therapeutics Market, Global, Generic Share, 2010 and 2017 54
Figure 35: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 55
Figure 36: Diabetes Therapeutics Market, Treatment Flow Algorithm 56
Figure 37: Diabetes Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017 57
Figure 38: Diabetes Therapeutics Market, Global, Diseased Population (million), 2002-2017 58
Figure 39: Diabetes Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 59
Figure 40: Diabetes Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 60
Figure 41: Diabetes Therapeutics Market, Global, Prescription Population (million), 2002-2017 61
Figure 42: Diabetes Therapeutics Market, Global, Major Companies, Revenue ($bn), 2009-2010 62
Figure 43: Obesity Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 65
Figure 44: Obesity Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 66
Figure 45: Obesity Therapeutics Market, Global, Generic Share, 2010 and 2017 67
Figure 46: Obesity Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 68
Figure 47: Obesity Therapeutics Market, Treatment Flow Algorithm - 1 69
Figure 48: Obesity Therapeutics Market, Treatment Flow Algorithm - 2 69
Figure 49: Obesity Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017 70
Figure 50: Obesity Therapeutics Market, Global, Diseased Population (million), 2002-2017 72
Figure 51: Obesity Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 73
Figure 52: Obesity Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 74
Figure 53: Obesity Therapeutics Market, Global, Prescription Population (million), 2002-2017 75
Figure 54: Dyslipidemia Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 78
Figure 55: Dyslipidemia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 79
Figure 56: Dyslipidemia Therapeutics Market, Global, Generic Share, 2010 and 2017 80
Figure 57: Dyslipidemia Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 81
Figure 58: Dyslipidemia Therapeutics Market, Treatment Flow Algorithm 82
Figure 59: Dyslipidemia Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017 83
Figure 60: Dyslipidemia Therapeutics Market, Global, Diseased Population (million), 2002-2017 84
Figure 61: Dyslipidemia Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 85
Figure 62: Dyslipidemia Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 86
Figure 63: Dyslipidemia Therapeutics Market, Global, Prescription Population (million), 2002-2017 87
Figure 64: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), 2010 89
Figure 65: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 90
Figure 66: Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 91
Figure 67: Obesity Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 107
Figure 68: Dyslipidemia Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 112
Figure 69: Metabolic Disorders Therapeutics Market, Company Shares, 2010 130
Figure 70: Metabolic Disorders Therapeutics Market, Pfizer Inc., SWOT Analysis, 2010 131
Figure 71: Metabolic Disorders Therapeutics Market, Novo Nordisk, SWOT Analysis, 2010 133
Figure 72: Metabolic Disorders Therapeutics Market, Sanofi, SWOT Analysis, 2010 134
Figure 73: Metabolic Disorders Therapeutics Market, Takeda, SWOT Analysis, 2010 135
Figure 74: Metabolic Disorders Therapeutics Market, Eli Lilly, SWOT Analysis, 2010 137
Figure 75: Metabolic Disorders Therapeutics Market, GSK, SWOT Analysis, 2010 138
Figure 76: Metabolic Disorders Therapeutics Market, Merck & Co. Inc., SWOT Analysis, 2010 139
Figure 77: Metabolic Disorders Therapeutics Market, Amylin Pharmaceuticals, SWOT Analysis, 2010 140
Figure 78: Metabolic Disorders Therapeutics Market, M&A, by Indication, 2010 141
Figure 79: Metabolic Disorders Therapeutics Market, M&A Deals by Deal Value ($m), 2009-2011 144
Figure 80: Metabolic Disorders Therapeutics Market, M&A Deals, By Geography, 2009-2011 146
Figure 81: Metabolic Disorders Therapeutics Market, Co-Development, By Indications, 2009-2011 147
Figure 82: Metabolic Disorders Therapeutics Market, Licensing Deals, By Geography, 2009-2011 158
Figure 83: GBI Research Market Forecasting Model 166

Companies Mentioned

 Pfizer Inc.
Novo Nordisk
Sanofi
Takeda
Eli Lilly
GlaxoSmithKline (GSK)
Merck & Co Inc
Amylin Pharmaceuticals